Developer docs
API playgroundTry for free, no card

Search company profiles

Kashiv BioSciences

Full company profile

uuid000042c

Namestring
Kashiv BioSciences
Legal namestring
Kashiv BioSciences, LLC
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Kashiv BioSciences is a vertically integrated biopharmaceutical company founded in 2011 and headquartered in Bridgewater, New Jersey, with operating facilities in Piscataway, New Jersey (150,000 sq.ft.), Chicago, Illinois (100,000 sq.ft.), Ahmedabad, India (125,000 sq.ft.), and a new facility under construction in Pipan, Gujarat, India. The company develops and manufactures biosimilars and complex peptide-based medicines, with capabilities spanning mammalian cell line development, microbial fermentation, analytical characterization, bioassay development, and fill-finish for prefilled syringes and vials. Its commercialized product portfolio includes two FDA-approved biosimilars — Releuko (filgrastim-ayow) and FYLNETRA (pegfilgrastim-pbbk) — for oncology supportive care, with later-stage pipeline assets including ADL-018 (omalizumab biosimilar with pending BLA/MAA across FDA, EMA, MHRA, and Health Canada), KSHB002 (abatacept biosimilar, Phase 1), undisclosed biosimilar candidates KSHB001 and KSHB011, a 505(b)(2) Carfilzomib program, and generic complex peptide programs KSHG004, KSHG005, and KSHG006.

Kashiv employs 600+ people globally, with over half holding advanced degrees, and operates through exclusive licensing and supply agreements with regional commercialization partners across the U.S. (Amneal), Europe/UK/India (Intas/Accord Healthcare), Canada (JAMP Pharma), Latin America (CRISTÁLIA), MENA (MS Pharma), and Mexico/Central America and Caribbean (Saya Biologics). Under this asset-light commercialization model, Kashiv handles regulatory registration, manufacturing, and supply while partners manage local sales, marketing, and distribution. Revenue streams include transaction-based product sales, licensing royalties/supply agreements, and contract manufacturing, with biosimilars sold at substantial discounts to originator biologics whose list prices typically exceed $100,000 per patient per year.

The company secured $150 million in debt financing from GoldenTree Asset Management in April 2025 and INR 648 crore (~$77 million) from Union Bank of India in December 2025 to fund capacity expansion including a 50,000-liter single-use commercial manufacturing facility in Pipan. In April 2026, Amneal Pharmaceuticals entered a definitive agreement to acquire Kashiv for up to $1.1 billion ($375M cash, $375M equity, up to $350M milestones), expected to close in H2 2026, creating a fully integrated global biosimilars platform.

Short descriptiontext

Kashiv BioSciences is a vertically integrated biopharmaceutical company that develops and manufactures biosimilars and complex peptide-based medicines, currently with two FDA-approved oncology supportive care biosimilars (Releuko, Fylnetra), a multi-asset global pipeline, and exclusive licensing partnerships covering US, Europe, Canada, Latin America, MENA, and Mexico/CAC regions.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersBridgewater, United States
HQ citystring
Bridgewater
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biosimilar development, biologic manufacturing, monoclonal antibody production, complex peptide therapeutics, fill-finish manufacturing
Industry1 code
PRIMARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biosimilar Pharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biosimilar Product Sales
TypeTransaction Fee
Description

Revenue from commercialized biosimilar products including Releuko (filgrastim) and Fylnetra (pegfilgrastim) sold through distribution partners in the U.S. and international markets

biospace.com
2Licensing and Supply Agreements
TypeLicensing Royalties
Description

Revenue from exclusive licensing and supply agreements with regional commercialization partners for biosimilars and complex peptide products. Kashiv handles regulatory registration, manufacturing, and supply while partners manage commercialization and distribution.

businesswireindia.com
3Contract Manufacturing
TypeManaged Services
Description

Manufacturing capabilities for biologics and specialty pharmaceuticals serving both internal pipeline products and potentially external partners

kashivbiosciences.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Infrastructure, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Releuko
Description

FDA-approved biosimilar (filgrastim-ayow) for oncology supportive care

kashivbiosciences.com
+3 more records
Core offering1 text field

Kashiv BioSciences is a fully integrated biopharmaceutical company that develops, manufactures, and commercializes biosimilars, complex generics, and peptide-based medicines. It operates vertically integrated capabilities spanning cell line development, bioassay development, analytical characterization, commercial-scale mammalian and microbial manufacturing, and fill-finish operations for prefilled syringes and vials. Its commercialized products include FDA-approved biosimilars Releuko (filgrastim-ayow) and FYLNETRA (pegfilgrastim-pbbk), with a pipeline targeting immunology, oncology supportive care, and respiratory indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Up to $150 billion in potential US biosimilar cost savings by 2026
+3 more records
Product overview1 text field

Kashiv BioSciences is a fully-integrated biopharmaceutical company developing biosimilars, complex generics, and peptide-based medicines. The product portfolio includes FDA-approved biosimilars Releuko (filgrastim-ayow) and FYLNETRA (pegfilgrastim-pbbk) for oncology supportive care, and a growing pipeline of biosimilar candidates including ADL-018 (omalizumab biosimilar with FDA, EMA, MHRA, and Health Canada submissions), KSHB002 (abatacept biosimilar), and undisclosed candidates KSHB011 and KSHB001. The company also develops complex medicines via 505(b)(2) and ANDA pathways, including Carfilzomib and peptide programs KSHG004, KSHG005, and KSHG006. Products are manufactured across integrated facilities in the US (New Jersey, Chicago) and India (Ahmedabad, Pipan).

Product and service10 records
1Releuko (filgrastim-ayow)
CategoryBiosimilar
Description

FDA-approved biosimilar providing filgrastim therapy to reduce infection risk in patients undergoing chemotherapy; sold through commercial partnerships in the U.S. market.

2FYLNETRA (pegfilgrastim-pbbk)
CategoryBiosimilar
Description

FDA-approved biosimilar providing long-acting pegfilgrastim therapy to reduce febrile neutropenia risk in chemotherapy patients; commercialized in the U.S. via Amneal.

3ADL-018 (Omalizumab biosimilar)
CategoryBiosimilar
Description

Biosimilar candidate to XOLAIR (omalizumab) for immunology and respiratory indications, with BLA filed at FDA, MAA accepted by EMA, validated by MHRA UK, and accepted by Health Canada.

4PEXEGRA
CategoryBiosimilar
Description

Health Canada approved biosimilar commercialized in Canada through distribution partnership with JAMP Pharma Corporation.

5FILRA
CategoryBiosimilar
Description

Health Canada approved biosimilar commercialized in Canada through distribution partnership with JAMP Pharma Corporation.

6KSHB002 (Abatacept biosimilar)
CategoryBiosimilar
Description

Biosimilar candidate referencing Orencia (abatacept) for immunology indications; Phase 1 clinical results announced in January 2026.

7Carfilzomib
Category505(b)(2) Program
Description

Oncology therapeutic candidate developed via the 505(b)(2) regulatory pathway, currently in development phase.

8KSHG004
CategoryGeneric Peptide
Description

Fertility peptide candidate in advanced development and filing stage under the generic peptide program.

9KSHG005
CategoryGeneric Peptide
Description

Fertility peptide candidate in advanced development and filing stage under the generic peptide program.

10KSHG006
CategoryGeneric Peptide
Description

Oncology and hormonal peptide candidate in development for FDA filing under the generic peptide program.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Definitive agreement for Amneal to acquire Kashiv BioSciences for $1.1 billion ($375M cash, $375M equity, up to $350M milestones). Creates fully integrated global biosimilars platform combining Kashiv's R&D, manufacturing, and regulatory capabilities with Amneal's commercial scale and distribution network. Expected to close H2 2026 pending shareholder approval and regulatory clearances.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-09
Description

Exclusive licensing and supply agreement for complex peptide product covering pan-European, UK, and Indian markets. Kashiv handles regulatory registration, manufacturing, and supply while Accord Healthcare manages commercialization and distribution.

3Saya Biologics
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-04
Description

Strategic partnership to register and commercialize a biosimilar supportive oncology therapy across Mexico and Central America and Caribbean (CAC) region covering 11 countries. Saya handles regulatory registration, commercialization, and distribution while Kashiv manages manufacturing and supply.

einpresswire.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-24
Description

Launch partnership for PEXEGRA and FILRA biosimilars in Canada. JAMP handles commercialization and distribution in Canadian market.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-09-11
Description

Licensing and supply agreement for omalizumab biosimilar (ADL-018) in Latin America markets.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-05
Description

MENA license and supply agreement for ADL-018, biosimilar candidate to Xolair (omalizumab).

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-07-01
Description

Exclusive licensing agreement for commercialization of proposed biosimilar to Xolair (omalizumab) in US market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-10-03
Description

Exclusive licensing agreement for development and commercialization of proposed biosimilar to Xolair (omalizumab). Subsequent termination with Amneal partnership replacing this arrangement.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pure-play biosimilar developer and manufacturer with a portfolio that includes an omalizumab biosimilar candidate — the same reference product as Kashiv's ADL-018. Alvotech and Kashiv previously had a co-development/licensing partnership on the omalizumab program that was later terminated, making them a directly comparable peer on pipeline, scale, and go-to-market model.

TypeDirect peer
Description

India-headquartered, fully integrated biosimilars developer and manufacturer with FDA/EMA-approved products across oncology, immunology, and diabetes. Kashiv's SVP Regulatory Affairs previously led Biocon's global biopharma regulatory function, and the companies compete head-to-head on mAb biosimilars and complex biologics manufacturing capacity in India.

TypeDirect peer
Description

Korean biosimilar pioneer with multiple EMA/FDA-approved biosimilars (Remsima/Inflectra, Truxima, Herzuma, etc.) and a vertically integrated manufacturing platform. Celltrion is a direct benchmark for Kashiv's vertically integrated biosimilar business model and competes in many of the same reference molecules (rituximab, trastuzumab, etc.).

TypeDirect peer
Description

Joint venture between Samsung Biologics and Biogen developing and commercializing biosimilars across oncology, immunology, and ophthalmology. Directly comparable to Kashiv as a focused biosimilar developer leveraging a large-scale biologics manufacturing platform.

TypeDirect peer
Description

U.S.-headquartered commercial-stage biosimilar company with approved products in oncology supportive care and a pipeline in ophthalmology and immunology. Highly comparable to Kashiv on U.S. commercial strategy, pipeline composition, and capital-markets profile.

6Sandoz
TypeBroad incumbent
Description

Novartis spin-off and global leader in generics and biosimilars with a broad portfolio of FDA/EMA-approved biosimilars and extensive in-house biologics manufacturing. Kashiv's SVP Regulatory previously led U.S. regulatory affairs at Sandoz; Sandoz serves as the incumbent benchmark for the addressable market Kashiv targets.

TypeDirect peer
Description

India-based biologics CDMO and biosimilar developer focused on biosimilars and complex biologics with mammalian and microbial manufacturing capabilities. Closely comparable to Kashiv's India-based biologics manufacturing strategy, including its Pipan expansion in Gujarat.

TypeDirect peer
Description

European biosimilar developer and manufacturer with commercial-stage biosimilars across oncology and immunology, plus its own GMP manufacturing. Comparable to Kashiv on integrated development-and-manufacturing model targeting the same Western and emerging-market biosimilar opportunities.

TypeBroad incumbent
Description

U.S. generic and specialty pharmaceutical company that has signed a definitive agreement to acquire Kashiv for up to $1.1B. Amneal is the broader incumbent generic-pharma platform that Kashiv's biosimilar assets are being integrated into, and overlaps with Kashiv on the Xolair biosimilar commercialization partnership.

TypeBroad incumbent
Description

Global generic and biosimilar pharmaceutical major with multiple FDA/EMA-approved biosimilars. Teva's broad biosimilar and generics portfolio represents the incumbent competitive landscape Kashiv competes within as it scales its partner-driven global commercialization model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kashiv BioSciences

Biosimilar Pharmaceuticalskashivbiosciences.com

Kashiv BioSciences is a vertically integrated biopharmaceutical company that develops and manufactures biosimilars and complex peptide-based medicines, currently with two FDA-approved oncology supportive care biosimilars (Releuko, Fylnetra), a multi-asset global pipeline, and exclusive licensing partnerships covering US, Europe, Canada, Latin America, MENA, and Mexico/CAC regions.

What Kashiv BioSciences does

Kashiv BioSciences is a vertically integrated biopharmaceutical company founded in 2011 and headquartered in Bridgewater, New Jersey, with operating facilities in Piscataway, New Jersey (150,000 sq.ft.), Chicago, Illinois (100,000 sq.ft.), Ahmedabad, India (125,000 sq.ft.), and a new facility under construction in Pipan, Gujarat, India. The company develops and manufactures biosimilars and complex peptide-based medicines, with capabilities spanning mammalian cell line development, microbial fermentation, analytical characterization, bioassay development, and fill-finish for prefilled syringes and vials. Its commercialized product portfolio includes two FDA-approved biosimilars — Releuko (filgrastim-ayow) and FYLNETRA (pegfilgrastim-pbbk) — for oncology supportive care, with later-stage pipeline assets including ADL-018 (omalizumab biosimilar with pending BLA/MAA across FDA, EMA, MHRA, and Health Canada), KSHB002 (abatacept biosimilar, Phase 1), undisclosed biosimilar candidates KSHB001 and KSHB011, a 505(b)(2) Carfilzomib program, and generic complex peptide programs KSHG004, KSHG005, and KSHG006.

Kashiv employs 600+ people globally, with over half holding advanced degrees, and operates through exclusive licensing and supply agreements with regional commercialization partners across the U.S. (Amneal), Europe/UK/India (Intas/Accord Healthcare), Canada (JAMP Pharma), Latin America (CRISTÁLIA), MENA (MS Pharma), and Mexico/Central America and Caribbean (Saya Biologics). Under this asset-light commercialization model, Kashiv handles regulatory registration, manufacturing, and supply while partners manage local sales, marketing, and distribution. Revenue streams include transaction-based product sales, licensing royalties/supply agreements, and contract manufacturing, with biosimilars sold at substantial discounts to originator biologics whose list prices typically exceed $100,000 per patient per year.

The company secured $150 million in debt financing from GoldenTree Asset Management in April 2025 and INR 648 crore (~$77 million) from Union Bank of India in December 2025 to fund capacity expansion including a 50,000-liter single-use commercial manufacturing facility in Pipan. In April 2026, Amneal Pharmaceuticals entered a definitive agreement to acquire Kashiv for up to $1.1 billion ($375M cash, $375M equity, up to $350M milestones), expected to close in H2 2026, creating a fully integrated global biosimilars platform.

Kashiv BioSciences firmographics

Firmographics
Name
Kashiv BioSciences
Legal name
Kashiv BioSciences, LLC
Website
https://kashivbiosciences.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
101–250 employees
Short description
Kashiv BioSciences is a vertically integrated biopharmaceutical company that develops and manufactures biosimilars and complex peptide-based medicines, currently with two FDA-approved oncology supportive care biosimilars (Releuko, Fylnetra), a multi-asset global pipeline, and exclusive licensing partnerships covering US, Europe, Canada, Latin America, MENA, and Mexico/CAC regions.
Ownership category
akta.pro rank

Kashiv BioSciences industry classification

Industry
Product category
Biosimilar Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAJAE
Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES)
Healthcare & Life Sciences/Biotechnology & Biologics/Bioprocessing & Biomanufacturing Technology (upstream/downstream, single-use, analytics)

Keywords

  • Biosimilar development
  • Biologic manufacturing
  • Monoclonal antibody production
  • Complex peptide therapeutics
  • Fill-finish manufacturing

Where Kashiv BioSciences is headquartered

Location

Headquarters

HQ city
Bridgewater
HQ country
United States
HQ region
North America

Offices5 records

Markets served

Kashiv BioSciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Infrastructure, Operations

Revenue model

  1. Biosimilar Product Sales: Revenue from commercialized biosimilar products including Releuko (filgrastim) and Fylnetra (pegfilgrastim) sold through distribution partners in the U.S. and international markets
  2. Licensing and Supply Agreements: Revenue from exclusive licensing and supply agreements with regional commercialization partners for biosimilars and complex peptide products. Kashiv handles regulatory registration, manufacturing, and supply while partners manage commercialization and distribution.
  3. Contract Manufacturing: Manufacturing capabilities for biologics and specialty pharmaceuticals serving both internal pipeline products and potentially external partners

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Kashiv BioSciences product offering

Product offering

Core offering

Kashiv BioSciences is a fully integrated biopharmaceutical company that develops, manufactures, and commercializes biosimilars, complex generics, and peptide-based medicines. It operates vertically integrated capabilities spanning cell line development, bioassay development, analytical characterization, commercial-scale mammalian and microbial manufacturing, and fill-finish operations for prefilled syringes and vials. Its commercialized products include FDA-approved biosimilars Releuko (filgrastim-ayow) and FYLNETRA (pegfilgrastim-pbbk), with a pipeline targeting immunology, oncology supportive care, and respiratory indications.

Product overview

Kashiv BioSciences is a fully-integrated biopharmaceutical company developing biosimilars, complex generics, and peptide-based medicines. The product portfolio includes FDA-approved biosimilars Releuko (filgrastim-ayow) and FYLNETRA (pegfilgrastim-pbbk) for oncology supportive care, and a growing pipeline of biosimilar candidates including ADL-018 (omalizumab biosimilar with FDA, EMA, MHRA, and Health Canada submissions), KSHB002 (abatacept biosimilar), and undisclosed candidates KSHB011 and KSHB001. The company also develops complex medicines via 505(b)(2) and ANDA pathways, including Carfilzomib and peptide programs KSHG004, KSHG005, and KSHG006. Products are manufactured across integrated facilities in the US (New Jersey, Chicago) and India (Ahmedabad, Pipan).

Differentiator

Problem solved

Functional benefit

Brands

  • Releuko: FDA-approved biosimilar (filgrastim-ayow) for oncology supportive care
  • FYLNETRA
  • PEXEGRA
  • FILRA

Products and services

  • Releuko (filgrastim-ayow) FDA-approved biosimilar providing filgrastim therapy to reduce infection risk in patients undergoing chemotherapy; sold through commercial partnerships in the U.S. market.
  • FYLNETRA (pegfilgrastim-pbbk) FDA-approved biosimilar providing long-acting pegfilgrastim therapy to reduce febrile neutropenia risk in chemotherapy patients; commercialized in the U.S. via Amneal.
  • ADL-018 (Omalizumab biosimilar) Biosimilar candidate to XOLAIR (omalizumab) for immunology and respiratory indications, with BLA filed at FDA, MAA accepted by EMA, validated by MHRA UK, and accepted by Health Canada.
  • PEXEGRA Health Canada approved biosimilar commercialized in Canada through distribution partnership with JAMP Pharma Corporation.
  • FILRA Health Canada approved biosimilar commercialized in Canada through distribution partnership with JAMP Pharma Corporation.
  • KSHB002 (Abatacept biosimilar) Biosimilar candidate referencing Orencia (abatacept) for immunology indications; Phase 1 clinical results announced in January 2026.
  • Carfilzomib Oncology therapeutic candidate developed via the 505(b)(2) regulatory pathway, currently in development phase.
  • KSHG004 Fertility peptide candidate in advanced development and filing stage under the generic peptide program.
  • KSHG005 Fertility peptide candidate in advanced development and filing stage under the generic peptide program.
  • KSHG006 Oncology and hormonal peptide candidate in development for FDA filing under the generic peptide program.

Quantifiable outcome

  • Up to $150 billion in potential US biosimilar cost savings by 2026
  • +3 more outcomes

Companies that use Kashiv BioSciences

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Kashiv BioSciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Kashiv BioSciences partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered flagship, core and regional.

  • Amneal PharmaceuticalsflagshipStrategic or Co-development Partner · 22 April 2026Definitive agreement for Amneal to acquire Kashiv BioSciences for $1.1 billion ($375M cash, $375M equity, up to $350M milestones). Creates fully integrated global biosimilars platform combining Kashiv's R&D, manufacturing, and regulatory capabilities with Amneal's commercial scale and distribution network. Expected to close H2 2026 pending shareholder approval and regulatory clearances.
  • Intas Pharmaceuticals / Accord HealthcarecoreChannel Partner/ Reseller/ Distributor · 9 February 2026Exclusive licensing and supply agreement for complex peptide product covering pan-European, UK, and Indian markets. Kashiv handles regulatory registration, manufacturing, and supply while Accord Healthcare manages commercialization and distribution.
  • Saya BiologicscoreChannel Partner/ Reseller/ Distributor · 4 February 2026Strategic partnership to register and commercialize a biosimilar supportive oncology therapy across Mexico and Central America and Caribbean (CAC) region covering 11 countries. Saya handles regulatory registration, commercialization, and distribution while Kashiv manages manufacturing and supply.
  • JAMP Pharma CorporationcoreChannel Partner/ Reseller/ Distributor · 24 September 2025Launch partnership for PEXEGRA and FILRA biosimilars in Canada. JAMP handles commercialization and distribution in Canadian market.
  • CRISTÁLIAregionalChannel Partner/ Reseller/ Distributor · 11 September 2025Licensing and supply agreement for omalizumab biosimilar (ADL-018) in Latin America markets.
  • MS PharmaregionalChannel Partner/ Reseller/ Distributor · 5 August 2025MENA license and supply agreement for ADL-018, biosimilar candidate to Xolair (omalizumab).
  • Amneal PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 July 2024Exclusive licensing agreement for commercialization of proposed biosimilar to Xolair (omalizumab) in US market.
  • AlvotechcoreStrategic or Co-development Partner · 3 October 2023Exclusive licensing agreement for development and commercialization of proposed biosimilar to Xolair (omalizumab). Subsequent termination with Amneal partnership replacing this arrangement.

Scale indicators10 records

Recent moves8 records

Expansion highlights6 records

Kashiv BioSciences competitors and assessment

Company assessment

Direct peers

  • Alvotech: Pure-play biosimilar developer and manufacturer with a portfolio that includes an omalizumab biosimilar candidate — the same reference product as Kashiv's ADL-018. Alvotech and Kashiv previously had a co-development/licensing partnership on the omalizumab program that was later terminated, making them a directly comparable peer on pipeline, scale, and go-to-market model.
  • Biocon Biologics: India-headquartered, fully integrated biosimilars developer and manufacturer with FDA/EMA-approved products across oncology, immunology, and diabetes. Kashiv's SVP Regulatory Affairs previously led Biocon's global biopharma regulatory function, and the companies compete head-to-head on mAb biosimilars and complex biologics manufacturing capacity in India.
  • Celltrion: Korean biosimilar pioneer with multiple EMA/FDA-approved biosimilars (Remsima/Inflectra, Truxima, Herzuma, etc.) and a vertically integrated manufacturing platform. Celltrion is a direct benchmark for Kashiv's vertically integrated biosimilar business model and competes in many of the same reference molecules (rituximab, trastuzumab, etc.).
  • Samsung Bioepis: Joint venture between Samsung Biologics and Biogen developing and commercializing biosimilars across oncology, immunology, and ophthalmology. Directly comparable to Kashiv as a focused biosimilar developer leveraging a large-scale biologics manufacturing platform.
  • Coherus BioSciences: U.S.-headquartered commercial-stage biosimilar company with approved products in oncology supportive care and a pipeline in ophthalmology and immunology. Highly comparable to Kashiv on U.S. commercial strategy, pipeline composition, and capital-markets profile.
  • Enzene Biosciences: India-based biologics CDMO and biosimilar developer focused on biosimilars and complex biologics with mammalian and microbial manufacturing capabilities. Closely comparable to Kashiv's India-based biologics manufacturing strategy, including its Pipan expansion in Gujarat.
  • Polpharma Biologics: European biosimilar developer and manufacturer with commercial-stage biosimilars across oncology and immunology, plus its own GMP manufacturing. Comparable to Kashiv on integrated development-and-manufacturing model targeting the same Western and emerging-market biosimilar opportunities.

Broad incumbents

  • Sandoz: Novartis spin-off and global leader in generics and biosimilars with a broad portfolio of FDA/EMA-approved biosimilars and extensive in-house biologics manufacturing. Kashiv's SVP Regulatory previously led U.S. regulatory affairs at Sandoz; Sandoz serves as the incumbent benchmark for the addressable market Kashiv targets.
  • Amneal Pharmaceuticals: U.S. generic and specialty pharmaceutical company that has signed a definitive agreement to acquire Kashiv for up to $1.1B. Amneal is the broader incumbent generic-pharma platform that Kashiv's biosimilar assets are being integrated into, and overlaps with Kashiv on the Xolair biosimilar commercialization partnership.
  • Teva Pharmaceutical Industries: Global generic and biosimilar pharmaceutical major with multiple FDA/EMA-approved biosimilars. Teva's broad biosimilar and generics portfolio represents the incumbent competitive landscape Kashiv competes within as it scales its partner-driven global commercialization model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kashiv BioSciences social profiles

Digital presence

Kashiv BioSciences compliance and trust

Trust signal

Compliance2 records

Kashiv BioSciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kashiv BioSciences leadership team

Management profile

Number of profiles

Profiles12 records

Kashiv BioSciences subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Kashiv BioSciences funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kashiv BioSciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kashiv BioSciences

What does Kashiv BioSciences do?

Kashiv BioSciences is a fully integrated biopharmaceutical company that develops, manufactures, and commercializes biosimilars, complex generics, and peptide-based medicines. It operates vertically integrated capabilities spanning cell line development, bioassay development, analytical characterization, commercial-scale mammalian and microbial manufacturing, and fill-finish operations for prefilled syringes and vials. Its commercialized products include FDA-approved biosimilars Releuko (filgrastim-ayow) and FYLNETRA (pegfilgrastim-pbbk), with a pipeline targeting immunology, oncology supportive care, and respiratory indications.

Is Kashiv BioSciences a public or private company?

Kashiv BioSciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Kashiv BioSciences founded?

Kashiv BioSciences was founded in 2011. It employs 101 to 250 people.

Where is Kashiv BioSciences based?

Kashiv BioSciences is headquartered in Bridgewater, United States, in the North America region.

How does Kashiv BioSciences make money?

Three revenue lines are on record. Biosimilar Product Sales are the primary driver. The others are licensing and Supply Agreements and contract Manufacturing.

Who are Kashiv BioSciences's main competitors?

Direct peers on record are Alvotech, Biocon Biologics, Celltrion, Samsung Bioepis, Coherus BioSciences, Enzene Biosciences and Polpharma Biologics. Broad incumbents are Sandoz, Amneal Pharmaceuticals and Teva Pharmaceutical Industries.

Does Kashiv BioSciences have an API?

No public API is recorded for Kashiv BioSciences.

What industry is Kashiv BioSciences in?

Kashiv BioSciences's product category is Biosimilar Pharmaceuticals. Its primary akta.pro industry code is HLAAAJAE, Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketWatchAmneal's Asthma Treatment Receives European Commission Marketing ApprovalThe European Commission granted marketing authorization for Adcomfo, an add-on treatment for severe persistent allergic asthma, developed by Kashiv BioSciences and Alvotech. The approval follows a positive EMA committee opinion in September, and the drug also received UK authorization in March. Amneal's biosimilar application for Novartis' XOLAIR is under review in the U.S.Law360Genentech, Novartis Sue Amneal Over Bid To Sell Xolair CopyGenentech and Novartis filed a patent infringement suit in Delaware federal court against Kashiv BioSciences, claiming its bid to sell a biosimilar copy of Xolair infringes their patents. The suit targets the allergy drug's biosimilar bid.Business TodayAmneal expands India operations after Kashiv buy, builds biosimilars portfolioAmneal Pharmaceuticals expanded its India operations after acquiring Kashiv BioSciences in August 2026, combining biologics capabilities. The company has invested over $300 million in India and now has 5,500 employees across eight FDA-approved facilities. It targets more than 12 commercial biosimilars and 20 additional products by 2030.PR NewswireBiosimilars Market worth $70.79 billion by 2036 - Exclusive Report by MarketsandMarkets™MarketsandMarkets projects the biosimilars market to grow from $37.39 billion in 2026 to $70.79 billion by 2036, a 6.6% CAGR. North America is expected to be the fastest-growing region, and oncology the leading indication, with monoclonal antibodies the top drug class.PR NewswireBiosimilars Market worth $70.79 billion by 2036 - Exclusive Report by MarketsandMarkets™MarketsandMarkets projects the biosimilars market to grow from $37.39 billion in 2026 to $70.79 billion by 2036, a 6.6% CAGR. North America is the fastest-growing region, and oncology is the leading indication, with monoclonal antibodies the top drug class.Drug Store NewsAmneal completes acquisition of Kashiv BioSciencesAmneal has completed its acquisition of Kashiv BioSciences, establishing a fully integrated global platform for biosimilar research, development, manufacturing, and commercialization. This strategic move aims to position Amneal as a leading provider of affordable medicines in the US by capitalizing on upcoming biologic loss of exclusivity events.NJBIZAmneal closes $1.1B Kashiv Biosciences acquisitionAmneal Pharmaceuticals Inc. has closed its acquisition of Kashiv BioSciences LLC, a Piscataway-based biosimilar developer, in a deal valued at over $1.1 billion. The transaction includes $375 million in cash, $375 million in equity at closing, and up to $350 million in potential milestone payments, establishing an integrated global biosimilars company with end-to-end R&D, manufacturing, and commercialization capabilities. The combination positions Amneal to launch multiple biosimilars annually and capitalize on an estimated $365 billion in branded sales facing patent expiration through 2028.The Times of India<b>US-based Amneal completes acquisition of Kashiv BioSciences to create global biosimilar platform</b>US-based Amneal Pharmaceuticals has completed its acquisition of Kashiv BioSciences, creating an integrated global biosimilars platform spanning research, development, manufacturing, and commercialisation. The combination brings together Kashiv's biologics capabilities with Amneal's commercial scale, giving the company access to a market where more than $300 billion in biologics are projected to lose exclusivity over the next decade. The transaction is expected to position Amneal as a major player in affordable biologic medicines, supporting a regular pipeline of biosimilar launches as part of its long-term growth strategy.GlobeNewswireAmneal Completes Acquisition of Kashiv BioSciences, Creating a Global Biosimilar LeaderAmneal Pharmaceuticals completed its acquisition of Kashiv BioSciences, creating an integrated global biosimilars platform with end-to-end R&D, manufacturing, and commercialization. The combination targets over $300 billion in projected biologics loss-of-exclusivity over the next decade, positioning Amneal to launch multiple biosimilars annually.Stock TitanAmneal Completes Kashiv Acquisition, Adds BiosimilarsAmneal Pharmaceuticals completed its acquisition of Kashiv BioSciences, creating a global biosimilar leader with integrated R&D, manufacturing, and commercialization capabilities. This strategic move aims to extend Amneal’s growth into the 2030s by capitalizing on biosimilars market opportunities expected from biologic loss of exclusivity. The acquisition promotes expanded access to biosimilar medicines and supports ongoing product launches.